HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. PSE Rx only?

This article was originally published in The Tan Sheet

Executive Summary

The Proprietary Association of Great Britain says the U.K. Medicine and Healthcare products Regulatory Agency should not make pseudoephedrine prescription-only in an April 25 release. In March MHRA proposed Rx-only status for PSE- and ephedrine-containing OTCs to prevent the manufacture of methamphetamine (1"The Tan Sheet" March 12, 2007, p. 4). "We urge the government not to take disproportionate measures to control pseudoephedrine that would affect legitimate usage and consumer needs," PAGB says. The group encourages PSE restrictions similar to U.S. measures such as sales limits and behind-the-counter or locked cabinet storage (2"The Tan Sheet" March 6, 2006, p. 5)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel